Gyre Therapeutics, Inc.
GYREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. Valued at $727.4M, GYRE is a small-cap name in its sector. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Market Cap
$727.4M
Beta
4.83
P/E (TTM)
—
P/E (Fwd)
114.33
EPS (TTM)
$-0.21
EPS (Fwd)
$0.06
ROE
-17.4%
ROA
-5.4%
Cash
$74.8M
Total Debt
$3.4M
Free CF
$1.9M
52W Change
-10.6%
Annual Financials
Cash vs Debt
Where GYRE stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, GYRE finished 6.13% below its 150-day moving average ($7.02) and 8.22% below its 200-day moving average ($7.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GYRE overbought or oversold?
At the August 31, 2026 close, GYRE's RSI(14) was 46.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $74.8M in cash comfortably exceeding the $3.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $1.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -17.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $102.3M to $116.6M.
A beta of 4.83 means GYRE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Gyre Therapeutics, Inc. and its sector.